An assessment on potential long-term health effects caused by antibiotic resistance marker genes in genetically modified organisms based on antibiotic usage and resistance patterns in Norway.

Abstract

Usage of antibiotics selects for resistant bacteria, resulting in reduced treatment options, and increased morbidity and mortality from microbial infections. Development of resistance in susceptible bacteria can occur through spontaneous mutation or horizontal gene transfer (HGT). Our current understanding of resistance development in bacterial pathogens is more descriptive than predictive in nature. That is, whereas the acquisition or development of new resistance determinants in bacteria can be retrospectively described relatively easily at the molecular, species and geographical distribution levels, the initial horizontal transfer events, the resistance gene donor, and the environmental location and conditions that produced the first generation of the resistant bacteria remain largely unknown. Without this latter knowledge and without a clear understanding of directional selection and genetic drift in natural bacterial populations, it is impossible to predict accurately further resistance development occurring through HGT. Some of the antibiotic resistance marker (ARM) genes used in the production of genetically modified organisms (GMO) encode resistance to antibiotics in clinical and veterinary use. Thus, concerns have been raised that the large-scale release of such genes in commercialized GMOs may increase the rate of, and broaden the locations where, bacteria horizontally acquire resistance genes.